Health-Related Quality of Life in Homozygous Familial Hypercholesterolemia: Results from an Online Survey.

Save

Background and Aims

Homozygous familial hypercholesterolemia (HoFH) is a rare inherited disorder characterized by dangerously high low-density lipoprotein cholesterol levels from birth, creating extreme risk of premature cardiovascular events if untreated. Health-related quality of life (HRQoL) associated with HoFH is not well characterized.

Methods

Across multiple countries, patients ≥12 years (y) with HoFH and caregivers ≥18y of patients with HoFH completed an online survey between April–May 2023 and May–August 2024. HRQoL was measured for patients and caregivers using the EuroQol 5 Dimension 5 Level (EQ-5D-5L) and the EuroQol visual analogue scale (EQ-VAS). Utility values were generated based on EQ-5D-5L responses using UK, US, and country-specific tariffs.

Median annual cost associated with receiving/accompanying patients to receive lipoprotein apheresis (LA) was estimated.

Results

Most patients (n = 8/15) were aged 25–34y; all caregivers (n = 9) were >35y. Mean age at diagnosis was 6.7y (patients)/4.8y (patients of caregivers). Eleven (73%) patients/six (67%) patients of caregivers were receiving LA.

EQ-5D-5L scores were lower in patients (0.74) than reported normal range for age-matched English population (0.79–0.95 [range 18–54y]) and average US adult score (0.85). EQ-VAS scores were lower for patients (mean 64/100) than reported US adult average score (80/100). Caregivers scored in normal range.

Patients receiving LA reported lower HRQoL than patients who were not. Patients on weekly LA reported markedly lower HRQoL than those receiving it less frequently. Median annual cost associated with undergoing LA was €4915/y (patients)/€5161/y (caregivers).

Conclusions

HoFH substantially and negatively impacts patient HRQoL. Receiving LA, whilst efficacious, is costly and demanding on patients’ and caregivers’ time.

Introduction

Homozygous familial hypercholesterolemia (HoFH) is an ultra-rare inherited genetic disorder that affects an estimated 1 in 300,000 individuals worldwide.1–3 HoFH is caused by bi-allelic pathogenic variants in key genes – most commonly LDLR, and less commonly APOB, PCSK9, and/or LDLRAP1 – that impair LDL receptor (LDLR)-mediated clearance of low-density lipoprotein cholesterol (LDL-C), resulting in extremely elevated levels of LDL-C in the bloodstream from birth.1 Clinical manifestations of HoFH often begin in childhood. Affected individuals may develop cholesterol deposition in the skin (xanthomas) and tendons (tendon xanthomas), which can be painful.4 Individuals with HoFH are at high risk of developing premature atherosclerotic cardiovascular disease (ASCVD).2 Severe disease can result in premature coronary artery disease and myocardial infarction, including during childhood or adolescence in some cases.5 Persistently elevated LDL-C levels can also lead to stroke and aortic valve disease, and early mortality if left untreated.4

Health-related quality of life (HRQoL) can also be significantly impaired in patients with HoFH6 (henceforth, “patients”). Due to the chronic nature of the condition, patients often experience limitations in physical activity/social engagement. Early-onset ASCVD, frequent hospitalizations, and lifelong treatment can lead to physical discomfort, anxiety about the future, and a sense of social isolation.

The combination of these factors can lead to a diminished quality of life (QoL) compared with the general population.6

Currently, there is no cure for HoFH, but treatments aim to lower LDL-C levels and reduce the risk of ASCVD events. Treatment options include lipid-lowering medications such as statins, ezetimibe, PCSK9 inhibitors, lomitapide, evinacumab, and lipoprotein apheresis (LA) in cases where medication alone is insufficient.1,7 LA is semi-invasive but highly effective in reducing LDL-C and is associated with reduced long-term risk of atherosclerotic cardiovascular disease and death.8 However, LA has to be undertaken on a regular basis, typically weekly or biweekly, as LDL-C levels increase after each session.9,10 Consequently, it is a time-consuming procedure, and patients with HoFH treated with LA have been reported to have a worsened Hospital Anxiety and Depression Scale (HADS) questionnaire score.11

The Role of Caregivers

An informal caregiver, further called “caregiver”, is defined as someone who looks after a family member, partner, or friend who needs assistance because of their illness, frailty, disability, mental health, or addiction problem and who cannot manage without caregiver support. The care that these caregivers provide is usually unpaid.12 Caregiving requires a significant level of responsibility, and although many caregivers find their caring role rewarding, it can be exhausting. Emotions such as guilt, resentment, and helplessness are common.

Some caregivers forego their income/career prospects to provide care, with many often coping with their situation alone, leading to feelings of isolation/depression. Caregiver QoL can be considerably affected by their care recipient’s condition/treatment burden.

Patient advocacy narratives have identified a substantial burden on caregivers of patients with HoFH due to the disease itself/the burden of receiving LA treatment, but demonstration of this in the literature is lacking.

Aims of This Study

The primary aim of this study was to capture HRQoL outcomes for patients with HoFH and their caregivers across multiple European countries. The secondary aim was to measure the disease burden on patients with HoFH and productivity loss to society from the perspectives of patients/caregivers associated with receiving LA, given the high impact of LA on HRQoL outcomes.

Materials and Methods

Study Design

Data were collected directly from patients with HoFH and their caregivers using an online self-completion survey approach, consisting of a disease-specific questionnaire developed by the researchers and a validated HRQoL instrument. Given the rarity of the condition, this approach allowed the collection of data that may not be available from other resources and can also be used to calculate the cost of treatment in patients/caregivers. All data were self-reported.

The survey also collected HRQoL data using the EQ-5D-5L13 to measure the HRQoL impact of HoFH on patients/caregivers. The EQ-5D-5L is a generic HRQoL measurement tool that consists of two parts: the EQ-5D descriptive system and the EuroQol visual analogue scale (EQ-VAS).14,15 The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Respondents of the EQ-5D-5L are asked to indicate their health state that day by selecting the most applicable statement to them from a list of five levels, ranging from “I have no problems” to “I have extreme problems”, in each of the five dimensions.

The EQ-VAS records the respondents’ self-rated health on a vertical VAS, ranging from 0 (“the worst health you can imagine”) to 100 (“the best health you can imagine”).14

Two surveys were developed—one for patients and one for caregivers—and both were hosted on Qualtrics, an online survey platform. The survey was developed originally in UK English with input from HoFH Ambassadors (patients/caregivers), facilitated by FH Europe Foundation, a European Patient Network committed to improve awareness, understanding, and access to diagnosis/treatment of inherited lipid conditions (specifically FH, HoFH, elevated lipoprotein(a), and familial chylomicronemia syndrome) in Europe and beyond.

Following collection of data from the English version of the surveys, the patient/caregiver surveys were translated into Arabic, French, German, Italian, and Spanish by Absolute Translations, an ISO 17100:2015-certified professional translation services provider that uses mother-tongue translators with a minimum of five years’ professional translation experience. The translated versions were subsequently reviewed and validated internally by native-language speakers to ensure that the translated content accurately reflected the original English-language survey and was appropriate for the target language. The contents of the translated surveys remained the same, with only two exceptions—language-specific versions of the EuroQol 5 Dimension 5 Level (EQ-5D-5L)16–20 were used and questions regarding nationality/country lived in were changed from multiple choice to text entry.

Setting

All data were collected remotely using the online surveys. Respondents could reside in any country but were required to understand written and spoken English, Arabic, French, German, Italian, or Spanish.

The survey link was shared via the website and newsletter of FH Europe Foundation. For the original English version of the survey, online recruitment occurred between April 27 and May 17, 2023. For the relaunch of the survey containing alternative language versions, recruitment was conducted via patient advocacy groups (PAGs), with links to FH Europe Foundation in the countries of interest.

These PAGs then shared the survey link via their own websites/networks. Recruitment occurred between May and August 2024.

Respondent Sample

Patients had to meet the following criteria: Age ≥12 yearsHave a self-reported diagnosis of HoFH (confirmed by genetic/blood test, family medical history, or physical symptoms); diagnosis was not independently verified against medical recordsAble to understand written and spoken English, Arabic, French, German, Italian, or SpanishAble and willing to complete an online questionnaire.

Caregivers had to meet the following criteria: Aged ≥18 yearsSelf-report as an informal caregiver (defined as somebody who provides care [including, but not limited to, tasks such as arranging healthcare visits, taking to appointments, helping around the house, etc.]) to a family member (eg, child, grandchild, parent, sibling), ward, or friend, and this care is not part of their profession (eg, nurse/care worker) for an individual who has been diagnosed with HoFH (confirmed by genetic/blood test, family medical history, or physical symptom; diagnosis was not independently verified against medical records)Able to understand written and spoken English, Arabic, French, German, Italian, or SpanishAble and willing to complete an online questionnaire.

Consent

An information sheet providing study details was presented to respondents at the beginning of the survey; informed consent to participate in the survey was requested before any survey questions were asked. Caregivers were required to confirm they had received permission from the person they care for to provide anonymous responses about their condition. Patients were asked to confirm they had the permission of their parent/guardian to take part in the survey if they were <16 years of age.

Survey Content

Each survey included a participant information sheet, informed consent form, and screening questions in addition to the main survey. Respondents who met the screening criteria and gave consent to participate were presented with the full survey, which consisted of the following sections: Questions about the patient’s HoFH/caregiving responsibilities and the health of the patient with HoFH cared forHealth service use questionsDemographic characteristics questionsQoL questions.

The format of the survey questions included multiple-choice entry and number entry. One open-ended question was included to allow respondents the opportunity to give further detail if they desired. The screening questions ensured only respondents meeting the inclusion criteria (see Section 2.3) could complete the survey.

Any respondents who did not meet the inclusion criteria were screened out and no data were retained.

Data Analysis

The raw data from the online surveys were downloaded from Qualtrics onto a secure server, checked, and exported to Stata 1821 to be cleaned/analyzed.

Demographic Characteristics and Details of HoFH Condition

Demographic data and data reporting the self-reported details of patients’ HoFH condition were reported using descriptive characteristics; the frequency and percentage of respondents in each respondent group were reported for categorical variables, and mean, standard deviation, minimum, and maximum values were reported for continuous variables.

HRQoL Outcomes

HRQoL was measured using the EQ-5D-5L and the EQ-VAS for patients/caregivers. Utility values were generated based on responses to the EQ-5D-5L using the US tariff for respondents from the US, the UK tariff for respondents from the UK, and any respondents from countries outside the US/UK who had completed the original version of the survey using the English EQ-5D-5L. Any respondents who had completed the survey after its relaunch completed their own language-specific version of the EQ-5D-5L; therefore, the country-specific tariffs were applied for these responses.

The Decision Sciences Unit crosswalk22 from 5L to 3L values was applied to generate utilities based on the UK tariff, in line with National Institute for Health and Care Excellence recommendations.23 Self-reported health was reported using descriptive statistics from data collected from the EQ-VAS.

Cost Burden of HoFH for Patients and Caregivers

Data were collected on patients’ frequency of appointments attended to receive LA treatment for HoFH (ie, weekly, biweekly, or less frequently than biweekly).

Productivity losses associated with treatment for HoFH represent the opportunity costs to society of treatment for HoFH. An individual must forego the opportunity to engage in alternative activities, such as paid/unpaid work, education, or enjoying leisure time, to attend a visit for LA and recover afterward. The value of the productivity losses associated with receiving LA for HoFH was calculated at the individual level by combining the time spent to attend visits (including travel time) and the time required to recover from the treatment with the monetary value of the alternative activities foregone to attend each visit and recover from the treatment.

Time spent engaging in unpaid work, education, or leisure activities was valued using relevant data sources from each country for the monetary value of those activities. These values/sources are listed in Supplementary Table S1. The monetary value of time spent in education was assumed equal to that of unpaid work for all countries.

All unit costs were inflated to 2024 prices – the date the survey was undertaken.

All cost data were first calculated in local currency and then converted to Euros using the average 2024 exchange rate. Cost data reported from respondents in Lebanon were excluded from the calculation of cost because of extreme instability in their currency over the course of this study, causing challenges with converting Lebanese cost data to a common currency for cross-country comparison.

Financial costs associated with attending LA appointments were estimated based on the cost of transport to each appointment. Respondents were asked to report their mode of transport and any associated costs (eg, for parking, public transport, or taxis) for their most recent appointment.

For each respondent, the productivity loss and out-of-pocket transportation costs were summed to estimate the total cost associated with one LA appointment. The annual cost of LA was then estimated by multiplying this total cost per appointment by the number of LA appointments attended over 12-months, based on each respondent’s reported treatment frequency.

Results

Demographic Characteristics and Details of Condition

Table 1 describes the demographic characteristics of patient/caregiver respondents. All caregiver respondents (n = 9) were >35 years of age, and most patient respondents (n = 8/15) were between ages 25 and 34 years. The modal nationality of patients was British (n = 5), and the modal nationality of caregivers (n = 5) was American.

Most patients (n = 8)/caregivers (n = 4) were employed full time, and less than half of patients (n = 6)/a minority of caregivers (n = 3) reported leaving education/employment or reducing work hours because of their condition/caregiving duties.Table 1Demographic Characteristics of Both Patient and Caregiver RespondentsN (%)aPatientsCaregivers(N = 15)(N = 9)How old are you? 18–24 years1 (6.7)- 25–34 years8 (53.3)- 35–44 years3 (20.0)4 (44.4) 45–54 years3 (20.0)3 (33.3) 55–64 years-1 (11.1) ≥65 years-1 (11.1)How old were you when you were diagnosed with HoFH? <1 year4 (26.7)- ≥1 year10 (66.7)- Unsure1 (6.7)-How old is the person with HoFH that you care for? <12 years-4 (44.4) 12–17 years-2 (22.2) 18–24 years-2 (22.2) 25–34 years-1 (11.1)What best describes your gender? Male4 (26.7)4 (44.4) Female11 (73.3)5 (55.56)What is your nationality?

British5 (35.7)1 (11.1) American1 (7.1)5 (55.6) Greek1 (7.1)- Lebanese3 (21.4)- Dutch1 (7.1)1 (11.1) Pakistani1 (7.1)- Romanian1 (7.1)1 (11.1) South African1 (7.1)- Algerian-1 (11.1)Which country do you currently live in? Greece1 (6.7)- Italy1 (6.7)1 (11.1) Lebanon3 (20.0)- Netherlands1 (6.7)1 (11.1) South Africa1 (6.7)- United Kingdom of Great Britain and Northern Ireland7 (46.7)1 (11.1) United States of America1 (6.7)5 (55.6) Austria-1 (11.1)What is your ethnic group?b White (English, Welsh, Scottish, Northern Irish, British, Irish, traveler, or any other White background)1 (16.7)1 (100.0) Asian or Asian British (Indian, Pakistani, Bangladeshi, Chinese, or any other Asian background)3 (50.0)- Arab2 (33.3)-What is the highest level of education or professional qualification you have? Secondary school completed2 (13.3)- Higher education below a degree2 (13.3)2 (22.2) Technical college or apprenticeship1 (6.7)- Undergraduate or bachelor’s degree7 (46.7)2 (22.2) Master’s or PhD degree3 (20.0)3 (33.3) No formal education-1 (11.1) Other qualification not listed-1 (11.1)How would you describe the community where you currently live?

Urban (living in a town or city where there are lots of different types of buildings)8 (53.3)3 (33.3) Suburban (living just outside of a city where most buildings are houses)5 (33.3)5 (55.6) Rural (living outside of a city where there is a lot of open space and fewer buildings)2 (13.3)1 (11.1)Which best describes your current employment or educational status?c Working full time (≥30 hours per week)8 (53.3)4 (44.4) Working part time (8–29 hours per week)4 (26.7)2 (22.2) Self-employed1 (6.7)- Student in higher/further education (eg, undergraduate degree, diploma, or postgraduate degree program)1 (6.7)- Unemployed2 (13.3)2 (22.2) Retired-1 (11.1)Has your employment or educational status changed because of your HoFH? Yes, I left school or further education2 (13.3)- Yes, I reduced my work hours from full time to part time3 (20.0)2 (22.2) Yes, I changed my role (such as taking a different type of job, or switching between employed and self-employed)1 (6.7)- No, my employment or educational status has not changed9 (60.0)6 (66.7) Yes, I retired or stopped work-1 (11.1)Are you the main caregiver for the person, or do you assist others with caregiving? I am the main caregiver-5 (55.6) I assist the main caregiver with caregiving responsibilities-3 (33.3) Unsure-1 (11.1)Notes: aDue to rounding, percentages may not add up to exactly 100%. bEthnicity data were only collected from respondents from the UK. cRespondents could provide multiple answers to this question; therefore, percentage may add up to >100%.Abbreviation: UK, United Kingdom.

Table 2 describes details of the HoFH condition of patient respondents/patients cared for by caregiver respondents. Most patients were diagnosed when they were older than 1 year old. The most common relationship of patients receiving help from a caregiver was a parent/guardian.

This was also shown by responses from caregivers. Most patients were currently receiving LA at the time of the survey (n = 11 [73%])/had received it previously (n = 3 [20%]). Similarly, most patients cared for by caregiver respondents were currently receiving LA (n = 6 [67%])/had received it previously (n = 1 [11%]).Table 2Details of the HoFH Condition of Patient Respondents and Patients Cared for by Caregiver RespondentsPatientsCaregivers(N = 15)(N = 9)Age of HoFH diagnosis of patient or patient cared for by caregiver, n (%) <1 year4 (26.7)- ≥1 year10 (66.7)8 (88.9) Unsure1 (6.7)1 (11.1)Age of diagnosis of patient cared for by caregiver if ≥1 year, mean ± SD, years6.7 ± 8.74.8 ± 2.3Help received from a caregiver due to condition, n (%) Yes3 (20.0)- No11 (73.3)- Prefer not to say1 (6.7)-Relationship of caregiver to patient, n (%) Parent/guardian2 (66.7)- Other1 (33.3)-Relationship of patient to caregiver, n (%) Child-7 (77.8) Partner/spouse1 (11.1) Other-1 (11.1)Currently receiving LA as treatment for HoFH, n (%) Yes11 (73.3)6 (66.7) No4 (26.7)2 (22.2) Unsure-1 (11.1)Previously received LA as treatment for HoFHa, n (%) Yes3 (75.0)1 (50.0) No1 (25.0)1 (50.0)Ever stopped LA as treatment for HoFHb, n (%) Yes, and have not restarted treatment3 (23.1)- Yes, but restarted treatment6 (46.2)2 (33.3) No4 (30.8)3 (50.0) Unsure-1 (16.7)Reason for stopping LA, n (%) Health service constraints (eg, does not provide apheresis in the area where you live)4 (40)- COVID-191 (10)2 (100.0) Financial reasons (eg, problems with insurance coverage)1 (10)- Personal circumstances to stop apheresis treatment1 (10)- Other4 (40)2 (100.0)Average frequency of LA treatment of patient or patient cared for by caregiver, n (%) Once per week3 (27.3)3 (50.0) Once every 2 weeks3 (27.3)- Less frequently than once every 2 weeks4 (36.4)3 (50.0) Unsure1 (9.1)-Notes: aThis question was only asked to respondents who were not currently receiving lipoprotein apheresis treatment. bOne illogical response to this question was excluded from analysis.Abbreviations: COVID-19, coronavirus disease 2019; HoFH, homozygous familial hypercholesterolemia; LA, lipoprotein apheresis; LDL, low-density lipoprotein; SD, standard deviation.

HRQoL Results

Table 3 shows the EQ-5D composite scores and EQ-VAS scores of the sample. The mean utility score calculated using the EQ-5D-5L was 0.74 for patients and 0.90 for caregivers. Scores from the EQ-VAS similarly showed lower patient (mean 64/100) compared with caregiver (mean 82/100) scores.Table 3EQ-5D Composite Scores and EQ-VAS Scores for Patients with HoFH and Caregivers of Patients with HoFHEQ-5D Composite ScoresEQ-VAS ScoresPatientsCaregiversPatientsCaregiversN159159Mean0.740.906482SD0.240.14209Median0.820.947085IQR0.35–0.990.63–0.9930–9565–91Abbreviations: EQ-5D, EuroQol 5 Dimension; EQ-VAS, EuroQol visual analogue scale; HoFH, homozygous familial hypercholesterolemia; IQR, interquartile range; SD, standard deviation.

Figure 1A and B show the proportion of responses for each domain of the EQ-5D-5L from patients and caregivers, respectively. Anxiety was the main contributor to the reduction in HRQoL scores from both groups. The most common self-reported reasons for anxiety in patients were heart issues they were experiencing (including heart disease and angina), fatigue, and financial stress.

Figure 1EuroQol 5 Dimension (EQ-5D) scores by domain reported by (A) patients and (B) caregivers.Image A: Bar graph showing frequency of scores for categories: No problems, Slight, Moderate, Severe, Unable/extreme. Y-axis: 0-100%. Legend: Mobility, Self care, Usual activities, Pain, Anxiety.

No problems: Mobility 73% (N=11), Self care 80% (N=12), Usual activities 67% (N=10), Pain 60% (N=9), Anxiety 20% (N=3). Slight problems: Mobility 13% (N=2), Self care 7% (N=1), Usual activities 7% (N=1), Pain 20% (N=3), Anxiety 47% (N=7). Moderate problems: Mobility 13% (N=2), Self care 7% (N=1), Usual activities 13% (N=2), Pain 13% (N=2), Anxiety 20% (N=3).

Severe problems: Self care 7% (N=1), Usual activities 13% (N=2), Pain 7% (N=1), Anxiety 13% (N=2). Image B: Similar graph, y-axis 0-100%. No problems: Mobility 100% (N=9), Self care 89% (N=8), Usual activities 78% (N=7), Pain 56% (N=5), Anxiety 56% (N=5).

Slight problems: Self care 11% (N=1), Usual activities 22% (N=2), Pain 44% (N=4), Anxiety 22% (N=2). Moderate problems: Anxiety 22% (N=2).A grouped bar graph showing EuroQol 5 Dimension 5 Level domain response frequencies for patients and caregivers.

Table 4A and B report the EQ-5D composite scores and EQ-VAS scores of the patients by current status of LA receipt (“currently receiving LA” or “not currently receiving LA”) and frequency of LA treatment (“once per week”, “once every 2 weeks”, “less frequently than once every 2 weeks”, or “unsure”). The corresponding data for caregivers are included in Supplementary Table S2A and S2B. Within this sample, patients who are currently receiving LA reported lower EQ-5D and EQ-VAS scores than patients who are not.

Patients who are receiving LA once per week also reported markedly lower EQ-5D and EQ-VAS scores than patients receiving it less frequently.Table 4Patient HRQoL Scores Reported by (A) Current Lipoprotein Apheresis (LA) Status and (B) Frequency of LA Received(A) Current LA StatusAre you currently being given LA treatment for your condition?YesNoTotalN (%)11 (73.3)4 (26.7)15 (100.0)EQ-5D score, mean ± SD0.73 ± 0.250.77 ± 0.230.74 ± 0.24EQ-VAS score, mean ± SD59.91 ± 21.0175.2 ± 18.7264.00 ± 20.96(B) Frequency of LA receivedHow frequently have you been given LA to treat your condition on average?Once per weekOnce every 2 weeksLess frequently than once every 2 weeksUnsureTotalN (%)3 (27.3)3 (27.3)4 (36.4)1 (9.1)11 (100.0)EQ-5D score, mean ± SD0.4 ± 0.00.9 ± 0.10.8 ± 0.20.90.7 ± 0.3EQ-VAS score, mean ± SD45.3 ± 21.675.0 ± 12.354.5 ± 21.180.059.9 ± 21.0Abbreviations: EQ-5D, EuroQol 5 Dimension; EQ-VAS, EuroQol visual analogue scale; LDL, low-density lipoprotein; QoL, quality of life; SD, standard deviation.

Patient and Caregiver Costs Associated with LA Treatment

The median productivity loss to patients (n = 8) was estimated to be €236.30 per visit (interquartile range [IQR] €172.03–€419.50). The median productivity loss to caregivers (n = 6) was estimated to be €237.64 per visit (IQR €199.65–€381.40).

The median out-of-pocket transport cost to patients (n = 5) was €2.76 per visit (IQR €0.00–€9.40). The median out-of-pocket transport cost to caregivers (n = 5) was €0 (IQR €0.00–€9.19).

The median total cost (productivity losses and out-of-pocket transport costs combined) to patients (n = 8) for one LA treatment visit was €236.30 (IQR €176.73–€419.50). The annual median cost to patients (n = 7; one patient was unsure of their LA treatment frequency) for all LA visits over a 12-month period was €4915.80 (IQR €2862.30–€22,325.94).

The median total cost (productivity losses/out-of-pocket transport costs combined) to caregivers (n = 6) for accompanying the patient they care for to one LA treatment visit was €242.23 (IQR €199.65–€381.40). The annual median cost to caregivers (n = 6) was €5161.49 (IQR €2395.74–€6850.05).

The cost for Lebanese respondents is reported in the local currency (Lebanese pounds) in Appendix A.

Discussion

The HRQoL outcomes calculated in this study from the EQ-5D and the EQ-VAS show that patients experience lower HRQoL than caregivers. The patient respondents in our sample reported lower utility scores compared with the adult population norms estimated for each country. The average UK population EQ-5D-5L values reported by McNamara et al24 for the age groups and sex included in the current study for patients (18–65+ years) ranged from 0.856–0.775 for females and 0.930–0.797 for males.24 This compares with the mean utility value reported in this study of 0.74 (range 0.35–0.99).

Comparing with US adult population norms25 shows a similar pattern; the US adult average score is 0.851.

Unlike the patient utility scores, the average EQ-5D-5L utility score calculated for caregivers in this study is not lower than those reported for the UK public.24 Compared with the age groups and sex of caregiver respondents in the current study, the UK population mean utility values for females aged 35 to ≥65 years range from 0.854–0.775 and for males ranges from 0.863–0.797. This compares with the mean EQ-5D-5L utility value of 0.90 (range 0.63–0.99) reported by caregivers in this study. Similarly, compared with the US adult population norms, the caregivers in our sample reported a mean utility score that is not lower than those estimated for the US population (0.851).25 Published HRQoL scores could not be identified to facilitate HRQoL comparisons with other comparable conditions.

The HRQoL results from this study demonstrate that patients who are currently receiving LA report a lower mean utility score than those who are not. A possible explanation for this could be that patients who are currently receiving LA have more severe illness than those not currently receiving LA. Alternatively, the negative effects of LA treatment itself could be impacting the HRQoL of recipients, resulting in lower EQ-5D scores than patients not currently receiving LA.

In addition, patients who were receiving LA more frequently reported a lower mean utility score, which could be due to the burden of LA being more likely to be captured because the patient was more likely to have completed the survey while recovering from their treatment.

The results of the present study differ from one previous publication which utilized the EQ-5D-5L to explore HRQoL in patients with HoFH.26 Mulder et al undertook a qualitative study involving 20 HoFH patients treated at 3 specialized HoFH centers in the Netherlands to explore how they deal with their disease in daily life.26 As part of the study HRQoL was measured; the median EQ-5D-5L health utility score was 0.839 [0.755; 0.887] and the mean visual analogue score was 75 (16.42), both markedly higher than the results of the current study, with the reported health utility score being only 5% below that of the Dutch population (0.887).27 However, only 2 patients in that cohort were being treated with LA. Patients also reported a high confidence in being treated in a dedicated HoFH center, which helped them cope with their disease.27

Other studies also report a reduction in HRQoL in patients with HoFH. Kayikcioglu et al11 studied HRQoL in 69 HoFH patients within the AHIT-1 registry in Türkiye, utilizing the Short Form-36 (SF-36) and HADS questionnaires. When compared with normative Turkish data, all domains of HRQoL, with the exception of vitality, were significantly impaired.11 Khoo et al28 also employed the SF-36 questionnaire to study the HRQoL in 15 HoFH patients in Malaysia.

The results of the SF-36 questionnaire revealed a reasonable quality of life; patients were mainly limited in the domains of general health and fatigue.28 Notably in both studies all patients were treated with LA. Indeed, whilst in the study of Khoo et al, 7 patients reported that LA significantly interfered with their lives, all 15 patients agreed that their health had benefited from the treatment.28 Nevertheless, these data do highlight the burden LA places on the HRQoL of patients with HoFH.

This study also highlights the costs incurred by patients and caregivers associated with receiving LA treatment. These were predominantly driven by productivity losses; the time forfeited to engage in work, education, or enjoying leisure time to attend a visit for LA and recover afterward. Such costs may not be immediately obvious to individuals unaffected by the disease.

The annual cost to patients/caregivers was similar, with a negligible difference due to a minimal difference in productivity losses per LA appointment between the patient/caregiver subgroups; however, the small samples prohibit robust, formal testing of any statistical significance of this difference.

The findings from this study demonstrate that HoFH imposes a substantial negative impact on patients’ HRQoL, and the societal cost of attending regular LA treatment is substantial. One-third of patients had to leave school/further education or reduce their work hours from full to part time due to their condition. This suggests that HoFH can substantially reduce the productivity of patients, a finding similar to that of Kayikcioglu et al,29 who identified almost one-third of HoFH patients from a nationwide Turkish survey who were unemployed; half of these patients cited HoFH as the barrier to finding employment.

Our study also demonstrated substantial productivity impacts of HoFH on caregivers; 40% of caregivers reported they had retired, stopped work, or reduced work hours from full to part time due to their caregiving role. This impact has caused financial concerns due to caregiving responsibilities, explicitly stated by one respondent: “My wife stopped her job as [redacted for anonymity] to care for our two children with HoFH. Her income loss was [substantial]”.

An analysis of the economic burden of the more prevalent and less severe heterozygous familial hypercholesterolemia (HeFH) demonstrated a substantial productivity burden associated with HeFH.30 Our findings extend this evidence by demonstrating considerable employment and caregiving impacts among patients with HoFH and their caregivers, suggesting that the burden of productivity loss extends across the spectrum of familial hypercholesterolemia and may be particularly pronounced in this severe form of the disease.

The nonfinancial burden imposed by HoFH has also been demonstrated in this study. For example, 60% of patients reported following a special diet because of their condition and 22% of caregivers reported the person they care for currently following a special diet due to their condition. Effective dietary management of HoFH requires input from a specialist dietician and the creation of individualized diet plans/lifestyle modifications, all of which require time and attention from patients/caregivers.31 Furthermore, patients in our study worried about the effects of their condition on people around them (“I hate to think of the burden my disease would put on someone else”), and caregivers reported feeling concern about the person they care for (“This [the patient’s life expectancy] weighs heavily in my mind”).

Together, these findings underscore the importance of assessing HRQoL in patients with HoFH, as clinical measures alone may not fully capture the substantial financial, psychosocial, and caregiver burden associated with the disease.

Limitations

The limitations of capturing HRQoL using the EQ-5D-5L in this cross-sectional study must also be explored; the values reported here show only a snapshot of a patient’s/caregiver’s life, which may not fully capture the HRQoL impact on these populations. Feedback from FH Europe Foundation ambassadors (consisting of HoFH patients and caregivers) on the survey noted the limitation of the EQ-5D-5L to fully capture HRQoL in this patient group. Furthermore, the EQ-5D-5L is not designed to specifically capture the impact on HRQoL of caregiving.

Future studies may consider the use of caregiving-specific HRQoL measures, such as the CarerQoL32 or generic QoL measurement tools, which are able to capture HRQoL over a longer period, such as the 36-Item Short Form Health Survey,33 which elicits data on an individual’s HRQoL over the past 4 weeks.

The type of LA procedure used and the nature and availability of vascular access could potentially influence the treatment burden with effects on treatment duration, recovery time, or the practical burden of undergoing apheresis. These factors were not captured in the current survey and future research should explore their potential impact on patient and caregiver burden.

Several respondents were unsure of their transport costs; therefore, the transport costs reported may underestimate the true cost of attending LA treatment. However, it is not likely that these missing data would change the outcomes of the financial costs substantially, given that the range of transport costs reported was small.

The current study did not assess HoFH-related complications, which represent a potentially important source of burden for both patients and caregivers. Future studies are warranted to better understand the relationship between disease-related complications and HRQoL outcomes.

This study also experienced challenges recruiting HoFH patients/caregivers across all of the European countries targeted due to the rare nature of this disease. The limited sample size may mean the results of this study are not a comprehensive picture of the HRQoL or cost burden of HoFH for patients and caregivers. It also restricted the ability to analyze the data by subgroups.

Furthermore, the small sample size precluded the use of inferential statistical analyses, limiting the ability to assess the statistical significance and generalizability of the findings.

Conclusions

This study demonstrates that HoFH imposes a substantial negative impact on the HRQoL of patients, with average reported EQ-5D-5L scores lower than general population scores. In addition, HoFH imposes a considerable financial burden through its effects on productivity. Our findings also highlight the impact of caring for patients on caregivers, with respondents reporting loss of income, worry, and having to give up/reduce hours worked.

Receiving LA as part of the current standard of care can be highly effective in reducing LDL-C but is demanding on patients’/caregivers’ time and energy.

Related articles

PubMed

Using Implementation Science to Improve Guidelines-Based Care to Lower Atherosclerosis Risk Due to Familial Hypercholesterolemia.

Purpose of the Review Implementation science, a multi-method research area that integrates input from constituents and content experts, has emerged as an important tool in improving implementation of evidence-based practices. This review summarizes three ongoing implementation studies focused on identification of patients with significantly increased risk for atherosclerotic cardiovascular disease (ASCVD) due to genomic risk such as familial hypercholesterolemia (FH) within a single health syst...

PubMed

Effectiveness and safety of atorvastatin/ ezetimibe fixed-dose combination in hypercholesterolemia: a systematic review and network meta-analysis.

Background Many patients fail to achieve low-density lipoprotein cholesterol (LDL-C) targets with statin monotherapy, calling for a combination of statins and ezetimibe. This systematic review and network meta-analysis evaluated the comparative effectiveness and safety of atorvastatin monotherapy, atorvastatin/ezetimibe free-equivalent combination (AS/EZ FEC), and fixed-dose combination (AS/EZ FDC) in patients with hypercholesterolemia. Methods Randomized controlled trials were retrieved from...